» Articles » PMID: 31547518

Rethinking Lupus Nephritis Classification on a Molecular Level

Overview
Journal J Clin Med
Specialty General Medicine
Date 2019 Sep 25
PMID 31547518
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The International Society of Nephrology/Renal Pathology Society (ISN/RPS) lupus nephritis (LN) classification is under reconsideration, given challenges with inter-rater reliability and resultant inconsistent relationship with treatment response. Integration of molecular classifiers into histologic evaluation can improve diagnostic precision and identify therapeutic targets. This study described the relationship between histological and molecular phenotypes and clinical responses in LN. Renal compartmental mRNA abundance was measured in 54 biopsy specimens from LN patients and correlated to ISN/RPS classification and individual histologic lesions. A subset of transcripts was also evaluated in sequential biopsies of a separate longitudinal cohort of 36 patients with paired samples obtained at the time of flare and at follow up. Unsupervised clustering based on mRNA abundance did not demonstrate a relationship with the (ISN/RPS) classification, nor did univariate statistical analysis. Exploratory analyses suggested a correlation with individual histologic lesions. Glomerular FN1 (fibronectin), SPP1 (secreted phosphoprotein 1), and LGALS3 (galectin 3) abundance correlated with disease activity and changed following treatment. Exploratory analyses suggested relationships between specific transcripts and individual histologic lesions, with the important representation of interferon-regulated genes. Our findings suggested that the current LN classification could be refined by the inclusion of molecular descriptors. Combining molecular and pathologic kidney biopsy phenotypes may hold promise to better classify disease and identify actionable treatment targets and merits further exploration in larger cohorts.

Citing Articles

Context aware machine learning techniques for brain tumor classification and detection - A review.

Amjad U, Raza A, Fahad M, Farid D, Akhunzada A, Abubakar M Heliyon. 2025; 11(2):e41835.

PMID: 39906822 PMC: 11791217. DOI: 10.1016/j.heliyon.2025.e41835.


Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis.

Wong C, Gao L, Xu Y, Chau M, Zhang D, Yap D Front Immunol. 2024; 15:1443153.

PMID: 39411720 PMC: 11473352. DOI: 10.3389/fimmu.2024.1443153.


Lupus Nephritis from Pathogenesis to New Therapies: An Update.

Roveta A, Parodi E, Brezzi B, Tunesi F, Zanetti V, Merlotti G Int J Mol Sci. 2024; 25(16).

PMID: 39201667 PMC: 11354900. DOI: 10.3390/ijms25168981.


Long-term outcomes and predictive factors of achieving low disease activity status in childhood systemic lupus erythematosus: a Chinese bicentric retrospective registered study.

Yu X, Deng J, Chen Q, Qiu S, Jiang C, Wu Y Front Immunol. 2024; 15:1369969.

PMID: 38915395 PMC: 11194373. DOI: 10.3389/fimmu.2024.1369969.


Galectin-3: action and clinical utility in chronic kidney disease.

Syn G, Lee Y, Lim Z, Chan G Int Urol Nephrol. 2024; 56(11):3535-3543.

PMID: 38861106 DOI: 10.1007/s11255-024-04107-4.


References
1.
Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

2.
Nielsen C, Lood C, Ostergaard O, Iversen L, Voss A, Bengtsson A . Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med. 2014; 1(1):e000026. PMC: 4246916. DOI: 10.1136/lupus-2014-000026. View

3.
Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D . The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2017; 18(2):293-307. PMC: 5817248. DOI: 10.1111/ajt.14625. View

4.
Liu Y, Deng W, Meng Q, Qiu X, Sun D, Dai C . CD8+iTregs attenuate glomerular endothelial cell injury in lupus-prone mice through blocking the activation of p38 MAPK and NF-κB. Mol Immunol. 2018; 103:133-143. DOI: 10.1016/j.molimm.2018.09.006. View

5.
Lerang K, Gilboe I, Steinar Thelle D, Gran J . Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus. 2014; 23(14):1546-52. DOI: 10.1177/0961203314551083. View